AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24408785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement
Number of subjects: 0
Study 24408785 — intervention group
Group type: COMPARATOR
Intervention: Routine replacement
Number of subjects: 0
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (patients >58 years of age)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (APACHE II score >22)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (diabetic patients)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (patients on vasopressor therapy)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (admitted with severe sepsis)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (creatinine ≤ 100 μmol/L)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (GCS ≤ 9)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin, equipotent doses ≥ 40 mg)
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 763
Study 21819615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 763
Study 20048489 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection with hyaluronic acid (HA) + standard of care (RICE)
Number of subjects: 158
Study 20048489 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (PL) + standard of care (RICE)
Number of subjects: 158
Study 17334536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg for 5 days)
Number of subjects: 23
Study 17334536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment in H. pylori-positive group
Number of subjects: 23
Study 15572316 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension (90 N)
Number of subjects: 49
Study 15572316 — intervention group
Group type: COMPARATOR
Intervention: Low-tension (45 N)
Number of subjects: 49
Study 15572316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (High-tension and Low-tension)
Number of subjects: 49
Study 11280168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg body wt)
Number of subjects: 26
Study 11280168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cola)
Number of subjects: 26
Study 9426843 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 3,200 mg/day for 3 months
Number of subjects: 28
Study 9426843 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) + hyperimmune CMV immunoglobulins (CMV Igs)
Number of subjects: 28
Study 9426843 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (ACV)
Number of subjects: 28
Study 9426843 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (ACV) with or without CMV Ig
Number of subjects: 28
Study 8097813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 1536
Study 2949910 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha-ANP (1-28) infusion at 1.2 pmol min-1 kg-1 for 3 hours
Number of subjects: 7
Study 2949910 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha-ANP (1-28) infusion
Number of subjects: 7
Study 2949910 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion (control)
Number of subjects: 7
Study 30629020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery (nonopioid analgesia, patient-directed oral intake, early ambulation)
Number of subjects: 46
Study 30629020 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (opioid analgesia, physician-directed diet)
Number of subjects: 46
Study 30629020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery
Number of subjects: 46
Study 30629020 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 46
Study 30503129 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone co-treatment during IVF
Number of subjects: 62
Study 30503129 — intervention group
Group type: COMPARATOR
Intervention: Non-GH-treated patients of the same age and ovarian reserve
Number of subjects: 62
Study 26904985 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response techniques (RRTs)
Number of subjects: 659
Study 24668315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 101
Study 24668315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 101
Study 24668315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 22690855 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole linseeds (2 tablespoons per day), n = 11
Number of subjects: 40
Study 22690855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground linseeds (2 tablespoons per day), n = 11
Number of subjects: 40
Study 22690855 — intervention group
Group type: COMPARATOR
Intervention: Whole linseeds (2 tablespoons per day), n = 9
Number of subjects: 40
Study 22690855 — intervention group
Group type: COMPARATOR
Intervention: Ground linseeds (2 tablespoons per day), n = 13
Number of subjects: 40
Study 20002592 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized antidepressant therapy for both depression and pain
Number of subjects: 250
Study 20002592 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 17658026 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-channel gastroscope and foreign body forceps plus symmetrical polypectomy shark retrieval snare
Number of subjects: 87
Study 17658026 — intervention group
Group type: COMPARATOR
Intervention: Standard gastroscope and foreign body forceps
Number of subjects: 87
Study 17658026 — intervention group
Group type: COMPARATOR
Intervention: Standard gastroscope and retrieval snare
Number of subjects: 87
Study 16219273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 47
Study 16219273 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 47
Study 12201325 — intervention group
Group type: EXPERIMENTAL
Intervention: eZ.on condom
Number of subjects: 43
Study 12201325 — intervention group
Group type: COMPARATOR
Intervention: Gossamer condom (control)
Number of subjects: 43
Study 12201325 — intervention group
Group type: COMPARATOR
Intervention: Avanti condom (control)
Number of subjects: 43
Study 10512093 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 7572748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55% of energy as carbohydrate and 30% as fat)
Number of subjects: 10
Study 7572748 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated-fat diet (45% of energy as fat and 40% as carbohydrates)
Number of subjects: 10
Study 7572748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 10
Study 2145237 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone, 100 mg t.d.s. added to optimal therapy
Number of subjects: 30
Study 2145237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 352140 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 29
Study 30936865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy protein supplement (6 grams/packet, twice per day for 8 weeks)
Number of subjects: 0
Study 30936865 — intervention group
Group type: COMPARATOR
Intervention: Soy protein supplement (6 grams/packet, twice per day for 8 weeks)
Number of subjects: 0
Study 27614706 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot dilation (OSD)
Number of subjects: 480
Study 27614706 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation (BD)
Number of subjects: 480
Study 27614706 — intervention group
Group type: COMPARATOR
Intervention: Sequential Amplatz dilation
Number of subjects: 480
Study 27614706 — intervention group
Group type: COMPARATOR
Intervention: Telescopic Alken dilation
Number of subjects: 480
Study 26032480 — intervention group
Group type: COMPARATOR
Intervention: Mental health intervention with a wait list control
Number of subjects: 19
Study 26032480 — intervention group
Group type: EXPERIMENTAL
Intervention: Community consultation
Number of subjects: 19
Study 23514955 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign approach among health workers
Number of subjects: 0
Study 23514955 — intervention group
Group type: COMPARATOR
Intervention: Control district (no intervention)
Number of subjects: 0
Study 21462258 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cue (attention to increase step length)
Number of subjects: 50
Study 21462258 — intervention group
Group type: EXPERIMENTAL
Intervention: External cue (auditory cue with instruction to take large step to the beat)
Number of subjects: 50
Study 21462258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medications
Number of subjects: 50
Study 19788967 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor <1 hour
Number of subjects: 4126
Study 19788967 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor >=5 hours
Number of subjects: 4126
Study 19788967 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor
Number of subjects: 4126
Study 16037752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) (EE/MT)
Number of subjects: 102
Study 16037752 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens (1.25 mg) alone (EE)
Number of subjects: 102
Study 12151959 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 without filgrastim
Number of subjects: 5
Study 12151959 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 with filgrastim
Number of subjects: 5
Study 12151959 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus vinorelbine (both with and without filgrastim)
Number of subjects: 5
Study 10065780 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/d; n = 14)
Number of subjects: 45
Study 10065780 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA (25 mg plus ethinyl E2 (EE); n = 13)
Number of subjects: 45
Study 10065780 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (500 mg/d; n = 15)
Number of subjects: 45
Study 8640470 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-suture method (Monsel's solution pack)
Number of subjects: 142
Study 8640470 — intervention group
Group type: COMPARATOR
Intervention: Suture method
Number of subjects: 142
Study 2307870 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and skin closure with a rotation flap
Number of subjects: 35
Study 2307870 — intervention group
Group type: COMPARATOR
Intervention: Simple excision
Number of subjects: 35
Study 6778456 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 12
Study 6778456 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate in combination with low doses of lithium
Number of subjects: 12
Study 30770294 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg per day)
Number of subjects: 1401
Study 27488837 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Epley maneuver
Number of subjects: 73
Study 27488837 — intervention group
Group type: COMPARATOR
Intervention: Gans maneuver
Number of subjects: 73
Study 23414086 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + SN + NRT
Number of subjects: 4000
Study 23414086 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + NRT
Number of subjects: 4000
Study 23414086 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + SN
Number of subjects: 4000
Study 23414086 — intervention group
Group type: COMPARATOR
Intervention: WEB
Number of subjects: 4000
Study 21825897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue sealing‐cutting device
Number of subjects: 128
Study 21825897 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 128
Study 19899545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 0
Study 16723322 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage PD group
Number of subjects: 41
Study 16723322 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced-stage PD group
Number of subjects: 41
Study 16723322 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 41
Study 16246943 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Kinesiology (AK)
Number of subjects: 81
Study 16246943 — intervention group
Group type: EXPERIMENTAL
Intervention: Open test phase
Number of subjects: 81
Study 12404166 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated human rotavirus vaccine 89-12
Number of subjects: 184
Study 10335001 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg twice daily)
Number of subjects: 7
Study 10335001 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg four times daily)
Number of subjects: 7
Study 10335001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Budesonide and Terbutaline)
Number of subjects: 7
Study 10335001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7567317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten oral suspension at a dose of 9.0 mg/kg
Number of subjects: 0
Study 7567317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten oral suspension at doses of 4.5, 9.0, and 13.5 mg/kg
Number of subjects: 0
Study 7567317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten oral suspension
Number of subjects: 0
Study 2343787 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to alcohol cues (sight and smell of favorite alcoholic drink)
Number of subjects: 8
Study 2343787 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood states
Number of subjects: 8
Study 2343787 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 8
Study 2343787 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood state
Number of subjects: 8
Study 7400486 — intervention group
Group type: EXPERIMENTAL
Intervention: Feingold's K-P diet
Number of subjects: 0
Study 7400486 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 31944893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental RECUR Brief Negotiated Interview for Oral Health (DR‐BNI)
Number of subjects: 241
Study 31944893 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (parent‐nurse conversation about child's future tooth eruption)
Number of subjects: 241
Study 31944893 — intervention group
Group type: EXPERIMENTAL
Intervention: DR‐BNI group
Number of subjects: 241
Study 29882725 — intervention group
Group type: EXPERIMENTAL
Intervention: Current safety measures at HWZs in Pakistan
Number of subjects: 0
Study 29882725 — intervention group
Group type: COMPARATOR
Intervention: MUTCD safety procedures
Number of subjects: 0
Study 29197345 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 120 mg
Number of subjects: 120
Study 29197345 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 120
Study 29197345 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg and Etoricoxib 120 mg
Number of subjects: 120
Study 29197345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25516371 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day)
Number of subjects: 33
Study 25516371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 33
Study 24361199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity vein bypass grafts (LEVBGs) with duplex ultrasound (DUS) surveillance
Number of subjects: 1404
Study 24361199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence with ultrasound surveillance
Number of subjects: 1404
Study 24361199 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft diameter <3 mm
Number of subjects: 1404
Study 24361199 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1404
Study 21362724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 55
Study 21362724 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg)
Number of subjects: 55
Study 19666639 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin suspended 3 days before surgery (Group 1)
Number of subjects: 109
Study 19666639 — intervention group
Group type: COMPARATOR
Intervention: Warfarin suspended <3 days or not at all (Group 2)
Number of subjects: 109
Study 19666639 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operation heparin treatment
Number of subjects: 109
Study 19666639 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed protocol of perioperative anticoagulation (suspension of warfarin not <3 days with low-molecular-weight heparin bridging stopped 12 h before surgery)
Number of subjects: 109
Study 17203292 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg oral dose (PO)
Number of subjects: 20
Study 17203292 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg intravenous dose (IV)
Number of subjects: 20
Study 15213052 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (30 g ethanol/d for 28 days)
Number of subjects: 8
Study 15213052 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin (30 g ethanol/d for 28 days)
Number of subjects: 8
Study 15213052 — intervention group
Group type: COMPARATOR
Intervention: Washout period
Number of subjects: 8
Study 11737928 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated obstructive sleep apnea (OSA)
Number of subjects: 0
Study 11737928 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of subtle functional vascular abnormalities
Number of subjects: 0
Study 9532989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 6275
Study 9532989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6275
Study 7978172 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 40
Study 7978172 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg droperidol
Number of subjects: 40
Study 2686489 — intervention group
Group type: EXPERIMENTAL
Intervention: O2/N2 (1:1)
Number of subjects: 42
Study 2686489 — intervention group
Group type: COMPARATOR
Intervention: O2/N2O (1:1)
Number of subjects: 42
Study 29232214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection above the median nerve
Number of subjects: 44
Study 29232214 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided corticosteroid injection below the median nerve
Number of subjects: 44
Study 26149961 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT with tension)
Number of subjects: 28
Study 26149961 — intervention group
Group type: COMPARATOR
Intervention: Sham (KT without tension)
Number of subjects: 28
Study 26149961 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 28
Study 24794514 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP and wavelet filtering (WF) for VEP detection
Number of subjects: 0
Study 24794514 — intervention group
Group type: EXPERIMENTAL
Intervention: Online BCI system using the proposed approach
Number of subjects: 0
Study 22022927 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance provided to mothers during pregnancy and when the child was 6 and 12 months old
Number of subjects: 625
Study 22022927 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of similar school children
Number of subjects: 625
Study 22022927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 625
Study 22022927 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of school children
Number of subjects: 625
Study 22022927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both randomized groups
Number of subjects: 625
Study 20519561 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 372
Study 18075766 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16219731 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment (binocular visual acuity <6/18 or <20/60 Snellen)
Number of subjects: 13569
Study 16219731 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment due to cataract or age-related macular degeneration
Number of subjects: 13569
Study 16219731 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment due to refractive error
Number of subjects: 13569
Study 16219731 — intervention group
Group type: COMPARATOR
Intervention: Cancer mortality
Number of subjects: 13569
Study 12433764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led follow up
Number of subjects: 203
Study 10342407 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (specific dosage and duration not mentioned)
Number of subjects: 0
Study 10342407 — intervention group
Group type: COMPARATOR
Intervention: Active placebo mimicking side-effects
Number of subjects: 0
Study 7739306 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm flashlamp‐pumped pulsed‐dye laser treatment
Number of subjects: 16
Study 7739306 — intervention group
Group type: COMPARATOR
Intervention: Untreated areas of scar
Number of subjects: 16
Study 2188905 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days regimen of diethyl carbamazine (DEC)
Number of subjects: 0
Study 2188905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days regimen of diethyl carbamazine (DEC)
Number of subjects: 0
Study 7380759 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent-awakening and breathing retraining (self-control) condition
Number of subjects: 24
Study 7380759 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 24
Study 30927415 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG trigger (5000 IU)
Number of subjects: 384